Alzheimer's disease

CASSAVA SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options

Retrieved on: 
Friday, February 23, 2024
Scientific misconduct, Court, Alzheimer's disease, FDA, News, Advertising, Data management, Neurobiology of Aging, Woman, Initiative, Safety, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, City University, Pharmaceutical industry

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) and reminds investors of the April 2, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $100,000 investing in Cassava stock or options between August 18, 2022 and October 12, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy

Retrieved on: 
Thursday, February 22, 2024
Retinitis pigmentosa, Liver, OTCQB, Cancer, Cataract, Alzheimer's disease, MD, Inflammation, Retina, Systemic disease, Patent, Swelling, Huntington's disease, Eye, Geography, Optical flow, Disease, Connective tissue, Biomarker, Anatomy, Kidney disease, Emaciation, Heart, Diagnosis, Conformation, Risk, Atrophy, Element, Cystic fibrosis, Parkinson's disease, Brain, Medical imaging

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.

Key Points: 
  • PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.
  • The present invention relates to systems and methods for visualizing eye anatomy for diagnostic and therapeutic purposes.
  • Furthermore, it allows for the detection and analysis of various conditions of the eye, such as, hydration, innervations, inflammation, circulation, nerve conduction, etc.
  • Some of the best-studied ocular conformational diseases include cataracts in the lens and retinitis pigmentosa in the retina.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 22, 2024
Scientific misconduct, City University, ALS, BBC World Service, Alzheimer's disease, Cassava Sciences, FDA, News, Food, Data management, Investor's Business Daily, Neurobiology of Aging, Complaint, Apoptosis, Safety, Initiative, Cassava, AMX0035, Biomarker, Patient, Cognition, Journal, Amylyx Pharmaceuticals, IBD, Evercore, Science, Defendant, Amyotrophy, Prescription, P.C, Pharmaceutical industry

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

Kirby McInerney LLP Reminds Investors of Lead Plaintiff Deadline in BioVie, Inc. (BIVI) Securities Class Action

Retrieved on: 
Wednesday, February 21, 2024
Scientific misconduct, Court, FDA, News, Macrocephaly, Alzheimer's disease, GCP, District court, Disease, Risk, Lung compliance, COVID-19, Patient, Clinical trial, Defendant, Pharmaceutical industry

Investors have until March 19, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 19, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On November 8, 2023, the Company filed its quarterly report with the SEC on Form 10-Q for the quarter ended September 30, 2023.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, February 18, 2024
Scientific misconduct, City University, ALS, BBC World Service, Alzheimer's disease, Cassava Sciences, FDA, News, Food, Data management, Investor's Business Daily, Neurobiology of Aging, Complaint, Apoptosis, Safety, Initiative, Cassava, AMX0035, Biomarker, Patient, Cognition, Journal, Amylyx Pharmaceuticals, IBD, Evercore, Science, Defendant, Amyotrophy, Prescription, P.C, Pharmaceutical industry

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

Asha Therapeutics to Present at AD/PD™ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year and Welcomes Two New SAB Members

Retrieved on: 
Friday, March 8, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, Other Technology, Research, Software, General Health, Science, Data Management, Clinical Trials, Community health, GSK, AbbVie, Huntington's disease, University, Mathematics, Emory University, Behavioral neurology, Pathology, School, Alzheimer's disease, Johnson & Johnson, Drug design, Gold, Bristol Myers Squibb, Johns Hopkins, Disorder, Psychiatry, Derek, UCB, Computer science, American Neurological Association, Asha, Parkinson's Foundation, Conference, Chemistry, Safety, Amelioration, CNS, Behavioural sciences, Medical school, MD, Neurology, Patient, Florida College, Disease, Publication, DRS, Pharmaceutical industry

Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.

Key Points: 
  • Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.
  • ASHA-091 restores normal mitochondrial function and has demonstrated disease modifying efficacy as a functional cure in preclinical disease models.
  • In preparation for clinical transition, Asha has appointed Dr. Michael Gold and Dr. Allan Levey to their Scientific Advisory Board.
  • Their expertise comes at a pivotal moment for Asha as we transition our first-in-class lead programs designed using our PRISM™ technology to clinical trials.

Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial

Retrieved on: 
Thursday, March 7, 2024
Mental Health, Neurology, Clinical Trials, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Blood, Natural history, University, Alzheimer's disease, Multimedia, Research, Pathology, News, ADAS, Conference, AFL, Patient, Disease, Psychiatry, ADNI, Dementia, MRI, Brain, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240307066794/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307066794/en/
    New 24-month data show sustained benefits across the disease spectrum from early to moderate dementia.
  • Analyses comparing the study participants to closely matched real world data and meta-analytical controls, showed significantly reduced disease progression in participants in the LUCIDITY trial.
  • In the early disease subgroup there was a significant reduction in transition to the dementia stage of AD.
  • Its secondary pharmacological action is symptomatic through increasing acetylcholine levels in parts of the brain essential for memory functions.

Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease

Retrieved on: 
Monday, March 4, 2024
Research, General Health, Pharmaceutical, Biometrics, Consumer, Clinical Trials, Science, Biotechnology, Neurology, Seniors, FDA, Health, Alzheimer's disease, Pathology, PET, Cerebrospinal fluid, Food, Breakthrough, Risk, Simoa, Biomarker, Deficit spending, Patient, CSF, Diagnosis, Plasma, Corporation, Medical device

The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis of life-threatening diseases with an unmet medical need.

Key Points: 
  • The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis of life-threatening diseases with an unmet medical need.
  • The Simoa p-Tau 217 test described in the Breakthrough Device application is a semi-quantitative in vitro diagnostic immunoassay intended for the measurement of p-Tau 217 concentration in plasma using the Quanterix HD-X immunoassay system.
  • The Breakthrough Device designation for the p-Tau 217 test underscores its potential to significantly impact Alzheimer's disease (AD) diagnosis and treatment.
  • However, Breakthrough Device designation does not guarantee that the FDA review and approval process will be shortened or that an application will be approved.

Cognito Therapeutics OVERTURE Clinical Trial in Alzheimer's Disease Published in Frontiers in Neurology

Retrieved on: 
Wednesday, March 6, 2024
Technology, Medical Devices, General Health, Neurology, Science, Consumer, Clinical Trials, Biotechnology, Health, Health Technology, Other Science, Research, Software, Hardware, Pharmaceutical, Data Management, Seniors, Cognito, Caregiver, Amyloid-related imaging abnormalities, Aes, HOPE, Alzheimer's disease, Political moderate, ARIA, Safety, Hope, Therapy, Memory, EEG, Tolerability, Patient, Clinical trial, Atrophy, MRI, Medical imaging

Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today the publication of the OVERTURE study results in Frontiers in Neurology .

Key Points: 
  • Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today the publication of the OVERTURE study results in Frontiers in Neurology .
  • The OVERTURE clinical trial was a randomized, double-blind, sham-controlled clinical trial conducted over a six-month period at 5 US clinical trial sites, involving participants with mild to moderate AD.
  • Participants were randomly assigned 2:1 to receive self-administered daily, one-hour Spectris therapy designed to evoke EEG-verified gamma oscillations or sham treatment.
  • “Publication of OVERTURE clinical trial results is an important step in our commitment to develop our technology-based therapeutic intervention in Alzheimer’s disease,” said Ralph Kern, M.D., MHSc, Chief Medical Officer of Cognito Therapeutics.

Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease

Retrieved on: 
Monday, February 26, 2024
Science, Neurology, Biometrics, Biotechnology, Research, General Health, Health, Health Technology, Mass, Mass General Brigham, Hospital, AdventHealth, Alzheimer's disease, Doctor of Philosophy, Medical school, MD, Physician, Quality of life, UPMC, Biomarker, Mayo Clinic, Patient, CSF, Disease, Diagnosis, Plasma, Harvard Medical School, Corporation, Workflow, Medical imaging

These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.

Key Points: 
  • These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.
  • This reach will provide greater access to patients for high-accuracy, non-invasive AD testing.
  • Traditional AD diagnosis has relied on combination of symptom presentation, brain imaging, and the detection of CSF biomarkers for AD.
  • “In our pursuit to build the global testing infrastructure for Alzheimer’s disease, Quanterix is pleased to work with several health systems whose combined networks treat millions of patients,” said Masoud Toloue, CEO of Quanterix.